WWB recently started offering retatrutide (LY-3437943), the GLP-1/GIP/glucagon triple agonist. I was one of the early buyers — placed my order on February 1st, 2026, received it February 18th. Order details: - 5x retatrutide 10mg vials - $45/vial ($225 total + $25 shipping) - Shipped from Wuhan, 17 days to Midwest US I sent two vials to Janoshik for full HPLC analysis. Results came back last week: Vial 1: 97.4% purity, primary degradation product at 1.8% Vial 2: 97.1% purity, primary degradation product at 2.1% For context, retatrutide is a significantly more complex molecule than semaglutide or tirzepatide. It's a 39-amino-acid peptide with a triple agonist mechanism and C20 fatty acid modification. Getting 97%+ on first-run synthesis from any Chinese lab is genuinely impressive. Eli Lilly's clinical supply was reportedly 98-99% but they have billion-dollar manufacturing infrastructure. The lyophilized cake was slightly off-white (vs pure white for their tirz/sema). My understanding is this is normal for reta due to the C20 fatty acid chain. I've been running 2mg/week for two weeks now. Subjectively: appetite suppression is noticeably stronger than tirz at equivalent dose timing. Some mild nausea at injection site for the first 12 hours. Energy levels feel elevated — possibly the glucagon receptor agonism contributing to lipolysis. Early days but I'm cautiously optimistic. Anyone else pulled the trigger on WWB reta?

97.1-97.4% for retatrutide from a grey market source is honestly better than I expected. The triple agonist structure makes synthesis and purification substantially harder. Most Chinese custom synthesis houses struggle to get above 95% on complex GLP-1RAs. A few technical questions: 1. Did Janoshik identify the degradation product? Could it be a truncated sequence or a deamidation product? 2. What was the mass spec confirmation? Was the molecular weight spot-on? 3. Any mention of aggregate content? At $45/vial for 10mg, that's $4.50/mg. For comparison, research-grade reta from US peptide suppliers (the ones that are still operating) runs $80-120 per 10mg. So significant cost savings if the quality holds.

Great questions. 1. Janoshik identified the main impurity as a closely related structural analog — likely a deletion sequence or incomplete fatty acid conjugation. Not a degradation product per se, more of a synthesis byproduct. Below the 2.5% threshold that would concern me. 2. Mass spec confirmed the correct molecular weight within instrument tolerance. M+H peak was where it should be. 3. Aggregation wasn't part of the standard test. I'd need to request SEC-HPLC specifically for that, which I haven't done. Good call though — aggregated peptides can trigger immune responses. The $4.50/mg pricing is exactly why I went for it. Even accounting for the Janoshik testing cost ($120 per sample x 2 = $240), my total investment in verified retatrutide is about $490 for 50mg of product. That's still dramatically cheaper than research suppliers.

I'll be the voice of caution here. Retatrutide is still in Phase 3 trials. We don't have complete safety data. The Phase 2 data from Eli Lilly was promising (up to 24% body weight loss at 12mg dose) but the glucagon receptor agonism adds a variable that tirz and sema don't have. Specifically, glucagon receptor activation can raise blood glucose and increase hepatic glucose output. The GLP-1 and GIP components counteract this, but the balance matters. Running grey market reta without medical supervision and regular blood work (liver panel, glucose, lipids) seems risky. Not saying don't do it. Saying monitor closely and have your doctor in the loop if at all possible.

100% agree with you. I'm running comprehensive blood work monthly — CMP, lipid panel, CBC, A1C, liver enzymes. My baseline bloods before starting reta were clean. I'll post my one-month labs when I have them. I'm also titrating conservatively. 2mg/week for the first 4 weeks, then 4mg, then reassess. The Phase 2 trial started at 1mg and escalated monthly, so I'm roughly following that protocol. No cowboy dosing. The glucagon concern is real. My fasting glucose actually went *down* slightly in the first two weeks (from 94 to 88 mg/dL), which suggests the GLP-1/GIP arms are dominating at this dose. But I'll be watching closely as I titrate up.